Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Anlotinib and Sintilimab injection
First Tracks Biotherapeutics
Advanced Hepatocellular Carcinoma
1 trial -
Anlotinib+ Liposomal Doxorubicin
First Tracks Biotherapeutics
Sarcoma
1 trial -
Anti-CD19 CAR-T
First Tracks Biotherapeutics
Acute Lymphoblastic Leukemia ,Lymphomas
1 trial -
Anti-PD-1 antibody
First Tracks Biotherapeutics
Chronic Hepatitis b
1 trial -
Apatinib
First Tracks Biotherapeutics
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
1 trial -
Apatinib
First Tracks Biotherapeutics
Thyroid
1 trial -
Apatinib
First Tracks Biotherapeutics
Non Small Cell Lung Cancer
1 trial -
Apatinib
First Tracks Biotherapeutics
Malignant Ascites
1 trial -
Apatinib
First Tracks Biotherapeutics
Lung Cancer
1 trial -
Apatinib
First Tracks Biotherapeutics
Intrahepatic Cholangiocarcinoma
1 trial -
Apatinib
First Tracks Biotherapeutics
Breast Cancer
1 trial -
Apatinib
First Tracks Biotherapeutics
Advanced Solid Tumors
1 trial -
Apatinib
First Tracks Biotherapeutics
Advanced Esophageal Squamous Carcinoma
1 trial -
Apatinib Combined With SHR-1210 Injection
First Tracks Biotherapeutics
Hepatocellular Carcinoma
1 trial -
Apatinib mesylate tablets
First Tracks Biotherapeutics
Gastric Cancer
1 trial -
Apatinib+ SHR-1210(Camrelizumab)
First Tracks Biotherapeutics
Esophageal Cancer
1 trial -
Apheresis and Bridging Therapy
First Tracks Biotherapeutics
Large B-cell Lymphoma
1 trial -
Ara-C Group
First Tracks Biotherapeutics
Acute Myeloid Leukemia
1 trial -
Arm 1: Standard Synchronous Group
First Tracks Biotherapeutics
Advanced Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Arm A
First Tracks Biotherapeutics
Esophageal Cancer
1 trial -
Atorvastatin
First Tracks Biotherapeutics
Myocardial Infarction
1 trial -
Aumolertinib
First Tracks Biotherapeutics
Lung Cancer
1 trial -
Autologous CD5 CAR T-cells
First Tracks Biotherapeutics
T-Cell Acute Lymphocytic Leukemia
1 trial -
Azacitidine
First Tracks Biotherapeutics
Philadelphia Chromosome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources